Human Papilloma Virus Testing Market Research Report 2025-2033 Featuring Abbott Laboratories, BioMerieux, Bio-Rad Laboratories, Epigenomics, Siemens Healthineers, Hologic, Qiagen, F. Hoffmann-La Roche
Human Papilloma Virus Testing Market
Dublin, July 29, 2025 (GLOBE NEWSWIRE) -- The "Human Papilloma Virus Testing Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" report has been added to ResearchAndMarkets.com's offering.The Human papillomavirus (HPV) Testing Market was USD 1.52 billion in 2024 and is expected to reach USD 3.62 billion by 2033, with a CAGR of 10.11% from 2025 to 2033. The growth is due to increasing awareness of cervical cancer, increased screening programs, and technological advancements in diagnostic technologies in global healthcare systems.
Internationally, the use of HPV testing is increasing with growing awareness regarding prevention of cervical cancer, government-sponsored screening programs, and WHO's initiative to eliminate cervical cancer as a public health issue. Developed countries have embraced HPV-based screening on a large scale, and developing nations are also adopting it, with the support of global health programs. Its high sensitivity and long-term risk prediction make it a method of choice in contemporary gynecological practice.Growth Driver in the Human Papilloma Virus (HPV) Testing Market
Increasing Awareness and Government Screening ProgramsInternational awareness programs and country-level screening programs have increased demand for HPV testing to a large extent. Governments in developed and emerging economies are adopting routine cervical cancer screening guidelines for women aged 30 and older. WHO organizations advocate for HPV testing as a key tool for early detection of cancer.
Greater awareness of HPV-associated cancers and immunization also reinforces demand. These efforts account for early diagnosis, prompt intervention, and overall reduction in HPV-associated disease burden, thus driving the market forward. SEP 2024, The United States, Australia, India, and Japan are rolling out a key initiative to fight cervical cancer across the Indo-Pacific, a preventable disease which is a significant health crisis in the region. This initiative is part of larger announcements made during the Quad Leaders Summit.Technological Breakthroughs in HPV TestingInnovation in diagnostic methods - like PCR, next-generation sequencing, and self-sampling kits - has revolutionized HPV testing by enhancing accuracy, accessibility, and convenience. Automated platforms, multiplex assays, and liquid-based cytology enable quicker turnaround times and large-scale screening. These technologies are particularly precious in resource-poor settings and enable wider adoption in public health systems. Ongoing R&D spending by diagnostic firms serves to improve test sensitivity and affordability, fueling additional market growth. June 2023, The WHO has prequalified a fourth test for human papillomavirus (HPV). Although most HPV infections will clear on their own, a few of the higher-risk types can cause cervical cancer, so HPV testing is important for cervical cancer screening.Rising Prevalence of HPV-Associated Cancers
Growing global incidence of HPV-related cancers, particularly cervical cancer, is a strong market driver. Cervical cancer is the fourth leading female cancer in the world according to the WHO, and the overwhelming majority of cases are caused by high-risk HPV types. Growing cases of cancer have driven the need for early detection strategies, putting HPV testing at the center of preventive medicine.
As healthcare professionals and patients strive for surefire diagnostic measures, HPV testing is also becoming a necessity in women's health care. An estimated 47,984 new cases of cancer occur each year in the United States in areas of the body where human papillomavirus (HPV) commonly occurs.Challenge in the Human Papilloma Virus (HPV) Testing Market
Limited Access in Low-Income CountriesIn spite of worldwide awareness, HPV testing is not readily available in low- and middle-income countries because of a lack of healthcare infrastructure and resources. There are few laboratory facilities, skilled professionals, and regular screening programs in most areas. Cultural taboo and sexual stigma also discourage HPV testing participation. This inequality avoids early diagnosis and enhances the risk of cervical cancer at advanced stages. It is essential to overcome these barriers using cost-effective point-of-care diagnostics and education initiatives for equitable market expansion.Exorbitant Cost of Sophisticated HPV Testing TechnologiesThe price of advanced HPV testing technologies, including PCR-based platforms and DNA sequencing, can be out of reach for healthcare systems and some patients. As developed nations implement these technologies into regular screening, the affordability gap restricts accessibility in resource-scarce settings. In addition, maintenance costs, quality assurance, and specialized staff requirements contribute to higher operating costs for clinics and laboratories. This cost factor hinders mass screening activities, particularly in developing countries.
Key Players Analyzed: Overview, Key Persons, Recent Development & Strategies, Financial Insights
Abbott Laboratories
BioMerieux SA
Bio-Rad Laboratories, Inc.
Epigenomics AG
Siemens Healthineers AG
Hologic Inc
Qiagen NV
F. Hoffmann-La Roche Ltd
Key Attributes:
Report Attribute
Details
No. of Pages
200
Forecast Period
2024 - 2033
Estimated Market Value (USD) in 2024
$1.52 Billion
Forecasted Market Value (USD) by 2033
$3.62 Billion
Compound Annual Growth Rate
10.1%
Regions Covered
Global
Key Topics Covered: 1. Introduction2. Research Methodology2.1 Data Source2.1.1 Primary Sources2.1.2 Secondary Sources2.2 Research Approach2.2.1 Top-Down Approach2.2.2 Bottom-Up Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Human Papilloma Virus Testing Market5.1 Historical Market Trends5.2 Market Forecast6. Human Papilloma Virus Testing Market Share Analysis6.1 By Application6.2 By Product6.3 By Technology6.4 By End Use6.5 By Countries7. Application7.1 Cervical Cancer Screening7.2 Vaginal Cancer Screening8. Product8.1 Consumables8.2 Instruments8.3 Services9. Technology9.1 Polymerase chain reaction (PCR)9.2 Liquid-based cytology9.3 Immunodiagnostics9.4 Hybrid Capture9.5 Others10. End Use10.1 Hospitals & Clinics10.2 Laboratories10.3 Others11. Countries11.1 North America11.1.1 United States11.1.2 Canada11.2 Europe11.2.1 France11.2.2 Germany11.2.3 Italy11.2.4 Spain11.2.5 United Kingdom11.2.6 Belgium11.2.7 Netherlands11.2.8 Turkey11.3 Asia-Pacific11.3.1 China11.3.2 Japan11.3.3 India11.3.4 South Korea11.3.5 Thailand11.3.6 Malaysia11.3.7 Indonesia11.3.8 Australia11.3.9 New Zealand11.4 Latin America11.4.1 Brazil11.4.2 Mexico11.4.3 Argentina11.5 Middle East & Africa11.5.1 Saudi Arabia11.5.2 UAE11.5.3 South Africa12. Porter's Five Forces Analysis12.1 Bargaining Power of Buyers12.2 Bargaining Power of Suppliers12.3 Degree of Rivalry12.4 Threat of New Entrants12.5 Threat of Substitutes13. SWOT Analysis13.1 Strength13.2 Weakness13.3 Opportunity13.4 Threat
14. Key Players Analysis
For more information about this report visit https://www.researchandmarkets.com/r/hxq1p6
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
Human Papilloma Virus Testing Market
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Melden Sie sich an, um Ihr Portfolio aufzurufen.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Option Care Health, Inc. (OPCH): A Bull Case Theory
We came across a bullish thesis on Option Care Health, Inc. on Brian's Substack by Brian Flasker. In this article, we will summarize the bulls' thesis on OPCH. Option Care Health, Inc.'s share was trading at $29.35 as of July 31st. OPCH's trailing and forward P/E were 23.29 and 19.65, respectively according to Yahoo Finance. A home infusion nurse in full PPE gown delivering treatments to a patient in their own home. Option Care Health (OPCH) has evolved into the dominant independent provider of home and alternate site infusion services in the U.S., originating from Madison Dearborn Partners' 2015 acquisition of Walgreens Infusion Services. The 2019 reverse merger with BioScrip and full divestiture by Walgreens and MDP by 2023 paved the way for OPCH to operate with full independence. Led by CEO John Rademacher and CFO Michael Shapiro, both with substantial equity stakes, OPCH has built a national infrastructure of 91 pharmacies and 99 infusion suites, covering 96% of the U.S. population. The company's integrated model provides cost-effective, high-quality infusion therapies in outpatient and home settings, capitalizing on a healthcare trend shifting treatments away from costly hospitals. This platform serves over 1,400 contracts with 800+ partners, including all top 10 national insurers. Acute therapies, though operationally complex, act as a competitive wedge, while chronic therapies anchor long-term recurring revenues. OPCH's mix—75% chronic, 25% acute—combined with a focus on generics and biosimilars, ensures resilience against pricing volatility. With its Advanced Practitioner (AP) model, OPCH is pushing clinical boundaries, managing more complex therapies in lower-cost settings and enhancing utilization of its already-built infrastructure. Only ~50% of its infusion suite capacity is currently utilized, leaving ample runway for capital-light growth. Despite industry concerns like drug pricing reforms and labor shortages, OPCH's embedded relationships, clinical capabilities, and scalable model offer strong visibility into cash flow and earnings. Trading at ~15.4x 2025 owner earnings with a 17.4% expected IRR, OPCH represents a high-quality compounder with an entrenched moat and significant upside. Previously, we covered a bullish thesis on Chemed Corporation by 310 Value in April 2025, which highlighted the durability of its earnings, temporary volatility in its subsidiaries, and disciplined share repurchases. The company's stock price has depreciated by approximately 29% since our coverage. This is because temporary segment headwinds persisted longer than expected. The thesis still stands as Chemed's core fundamentals remain intact. Brian Flasker shares a similar view but emphasizes OPCH's capital-light model and payer-aligned infrastructure. Option Care Health, Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 40 hedge fund portfolios held OPCH at the end of the first quarter, which was 40 in the previous quarter. While we acknowledge the potential of OPCH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CBS News
an hour ago
- CBS News
Dr. Mehmet Oz says applications for $50 billion rural hospital fund will go out "in early September"
Washington — Centers for Medicare & Medicaid Services Administrator Dr. Mehmet Oz said Sunday that applications for a fund for rural hospitals will go out in "early September" in the wake of Medicaid cuts in President Trump's signature piece of legislation passed by Congress last month. "We're putting $50 billion. The president wants this, the Congress wants this," Oz said on "Face the Nation with Margaret Brennan." Mr. Trump signed the so-called "big, beautiful bill" into law last month, which included a number of his second-term priorities from tax cuts to increased spending on border security, defense and energy production. The legislation was paid for in part by significant cuts to health care programs, like Medicaid, which provides government-sponsored health care for low-income and disabled Americans. Among the cuts to Medicaid, the new law will lower provider taxes, which states use to help fund their portion of Medicaid costs. Lawmakers sought to supplement the cuts with a rural hospital stabilization fund after some GOP senators expressed concern over how rural hospitals could be impacted by the Medicaid restrictions, allocating $50 billion for rural hospitals. Oz outlined that rural hospitals will receive applications for the fund in early September. He said the money is designed to help with "workforce development, right-sizing the system and using technology to provide things like telehealth that can change the world." "Imagine if we can change the way we think about the delivery of health and make it more about getting people healthy who can thrive and flourish and be fully present in their own lives and as Americans," Oz said. The new law will also make changes to Medicaid work requirements for some able-bodied adults, along with more frequent eligibility checks. The Congressional Budget Office estimated that the legislation would result in 11.8 million Americans losing health coverage under Medicaid over the next decade. Oz touted the work requirements, saying "every Democratic president and Republican president has said that the foundation of a healthy welfare system, a social system of support, is work." He outlined that the requirements can also be met through community engagement, education and in caretaking roles, and that the administration began pursuing pilot programs when the bill was signed to demonstrate how technology can support the changes. But Brennan noted that according to KFF Health Policy, 92% of adult Medicaid recipients already are working or are caregivers or qualify for other exceptions. Oz said "they're fine." "We want to help connect you to the job market and get you into work," Oz said of people who are considered able-bodied. "The goal of health care insurance is to catalyze action in the right direction, to get you healthier, to give you agency over the future, so you recognize you matter, and you should have a job, therefore, to go out and change the world."
Yahoo
an hour ago
- Yahoo
Jessie J admitted to hospital for infection just weeks after breast cancer surgery
Jessie J has revealed she was admitted to hospital after developing symptoms that 'pointed towards a blood clot on the lung'. However, the 37-year-old shared that doctors instead discovered an 'infection' and 'a little fluid', weeks after undergoing surgery for breast cancer. Jessie said she has since discharged herself from the same hospital where she was treated after breast cancer surgery, announcing in July that she had since seen 'no cancer spread'. Jessie J says breast cancer surgery 'isn't a speedy recovery and it isn't meant to be' In a post on Instagram, the Price Tag singer told her followers: 'Six weeks post surgery and I was back in the same ward I was after my surgery. Not expected or planned. 'I had and still have symptoms that pointed towards a blood clot on the lung, it is not a blood clot thank god. 'They ran a lot of tests, which ended up showing I have an infection (still trying to figure out what) and a little fluid on my lungs. 'Finding it hard to breathe in, but I discharged myself last night (I hate being in hospital) and will continue the investigation as an outpatient.' She went on to say it was 'frustrating' that her career plans had to change due to her surgery and hospital visits, and added that she had been 'working so hard to get to this point and excited to do it all'. When to See Your GP About Cancer Jessie continued: 'I know for me, the true hard journey of this whole thing physically was the day I went into surgery. 'The recovery physically is far from quick or easy, and mentally it's been the most challenging time for me, especially as a mum with a toddler and being unable to be the mother I usually am.' The former coach on The Voice said her visit to hospital was a 'reminder to myself to slow down' even though she felt she was already at a slow pace. Recommended reading: Singer Jessie J diagnosed with 'early breast cancer' and reveals surgery plans Freddie Flintoff praises NHS staff who cared for him after serious car crash Michael Palin 'slightly unsteady' as he admits he's 'prepared for death' Jessie added: 'This isn't a speedy recovery and it isn't meant to be. 'As an ADHD Aries, fire breathing dragon t-rex, I can do it myself, I'm always ok woman. That slow pace has been a hard reality to accept to be honest. 'I love moving and working and being up and active but I can't be right now, and that's what it is, and I am finding the strength knowing that all can be adjusted to align with a slower pace and the support of my very small inner support circle.'
